High In Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea
High In Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea
复制标题
DOI：
10.1128/aac.03090-14
复制
发表时间：
2014-09-01
影响因子：
4.9
通讯作者：
Unemo, Magnus
中科院分区：
文献类型：
--
作者：
Jacobsson, Susanne;Golparian, Daniel;Unemo, Magnus
我们评估了新型螺嘧啶三酮AZD0914(DNA旋转酶抑制剂)对淋球菌临床分离株和国际参考菌株(n=250)的活性，包括多种多重耐药和广泛耐药的菌株。AZD0914的最低抑菌浓度大大低于目前或以前推荐的大多数其他抗菌药。AZD0914应在适当的随机和对照临床试验中进一步评估，包括体外选择、体内出现和耐药机制、人体药代动力学/药效学、最佳剂量和性能。
We evaluated the activity of the novel spiropyrimidinetrione AZD0914 (DNA gyrase inhibitor) against clinical gonococcal isolates and international reference strains (n = 250), including strains with diverse multidrug resistance and extensive drug resistance. The AZD0914 MICs were substantially lower than those of most other currently or previously recommended antimicrobials. AZD0914 should be further evaluated, including in vitro selection, in vivo emergence and mechanisms of resistance, pharmacokinetics/pharmacodynamics in humans, optimal dosing, and performance, in appropriate randomized and controlled clinical trials.